TNXP Tonix Pharmaceuticals Holding Corp.
Price Chart
Executive Summary
Tonix Pharmaceuticals announced a second GPO agreement for TONMYA, effective June 1, 2026, adding ~17 million commercial lives and bringing total commercial coverage to ~52 million lives (29% of U.S. commercial market). TONMYA is also available under Medicaid in most states (~75 million beneficiaries). This expands patient access during the early commercial launch phase but does not provide revenue or prescription data.
Actionable Insight
Monitor future 8-Ks or press releases for TONMYA prescription volume, net revenue, and Medicare coverage updates. The coverage expansion is a necessary but insufficient condition for commercial success — actual script data will determine revenue trajectory.
Key Facts
- Second GPO agreement effective June 1, 2026, adds ~17 million U.S. commercial lives (10% of ~177 million total commercial lives).
- Total commercial coverage now ~52 million lives (29% of U.S. commercial market).
- TONMYA available under Medicaid in most states, representing ~75 million Medicaid beneficiaries.
- First GPO agreement announced May 6, 2026, provided access to ~35 million commercial lives.
- Discussions with Medicare continue to advance.
Financial Impact
No revenue, prescription, or pricing data disclosed. Coverage expansion is a positive access milestone but unquantified in dollar terms.
Risk Factors
- No revenue or prescription data disclosed — coverage does not guarantee utilization.
- Medicare coverage discussions are ongoing but not finalized.
- Competition from existing fibromyalgia treatments and generic cyclobenzaprine.
- Company's historical stock performance on prior filings has been poor (avg T+20 alpha -10.82%, 17% win rate).
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-027621 |
| Exhibit: ex99-01.htm | 0001493152-26-027621 |
| Document: 0001493152-26-027621-index-headers.html | 0001493152-26-027621 |
| Document: 0001493152-26-027621-index.html | 0001493152-26-027621 |
| Document: 0001493152-26-027621.txt | 0001493152-26-027621 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 9, 2026
today
|
Insider Cluster
| $11.44 awaiting T+5 | awaiting T+5 | — | $11.71 (+2.36%) |
|
Jun 8, 2026
1d ago
|
8-K
| $11.05 awaiting T+5 | awaiting T+5 | — | $11.71 (+5.97%) |
|
May 15, 2026
25d ago
|
8-K
| $15.74 $12.77 | ▼ −18.87% | ▼ −19.83% | $11.71 (−25.60%) |
|
May 14, 2026
26d ago
|
Press Release
| $14.09 $14.00 | ▼ −0.64% | ▲ +0.08% | $11.71 (−16.89%) |
|
May 11, 2026
29d ago
|
8-K
| $13.28 $14.26 | ▼ −7.38% | ▼ −7.30% | $11.71 (+11.82%) |
|
Apr 29, 2026
5w ago
|
8-K
| $12.40 $13.50 | ▲ +8.87% | ▲ +5.76% | $11.71 (−5.56%) |
|
Apr 23, 2026
6w ago
|
8-K
| $12.49 $12.40 | ▼ −0.72% | ▼ −2.20% | $11.71 (−6.24%) |
|
Apr 15, 2026
7w ago
|
Press Release
| $14.34 $13.11 | ▼ −8.58% | ▼ −10.22% | $11.71 (−18.34%) |
|
Mar 26, 2026
10w ago
|
Press Release
| $13.75 $13.90 | ▲ +1.09% | ▼ −0.54% | $11.71 (−14.84%) |
|
Mar 23, 2026
11w ago
|
Press Release
| $15.34 $13.75 | ▼ −10.37% | ▼ −9.94% | $11.71 (−23.66%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access